The management of HLB has called for a shareholder's meeting tomorrow (Nov 18). They claim to want to address the allegations we have made against them.
What we want is the truth, something that they have been hiding all this time.
As investors we demand that the company release the full minutes of the FDA meeting and also answer these six questions.
1. Did Rivoceranib fail the phase 3 clinical trial based on the overall survival rates?
2. The chances of the US Food and Drug Administration approving a drug which failed its primary objective is low. Do you agree?
3. We heard rumours that based on ANGEL, China is looking at withdrawing the drug from the market. How true is that?
4. In the phase 3 trial results, the death rate for third line cancer patients is faster than the placebo group. How do you explain that?
5. Is it true that Jin Yang-Gon has no experience in medicine and his only experience in running a business before HLB was a beer and chicken wings bar?
6. How much of HLB's convertible bond and warrants did Jin Yang-Gon buy over the past three years?
Comments